by the Department of Veterans Affairs (VA), 12 and specific clinics for the treatment of hepatitis C have been set up in several VA medical centers throughout the United States.
The costs of treating HCV infection with interferon-based regimens are substantial. The total cost of interferon and ribavirin therapy to the VA in fiscal year 2001 was approximately $19 million. Since the approval of peginterferon alfa-2b and peginterferon alfa-2a, and the unbundling of ribavirin from interferon, the costs of therapy increased to approximately $60 million in fiscal year 2003. It was not known at our facility whether the treatment guidelines for the duration of therapy, monitoring of adverse events, laboratory test values, and subsequent dosage reductions were appropriately followed. The aim of this study was to retrospectively evaluate the monitoring and duration of therapy of patients with HCV infection and to determine the costs of treatment outside the recommended guidelines.
Methods. All patients evaluated in this retrospective study were veterans of the U.S. military and were enrolled in the HCV clinic. Patients who had received treatment for HCV with a combination of interferon and ribavirin (Rebetron, Schering, Kenilworth, NJ) from 1998 to 2001 were identified in the computerized database. Once these patients were identified, the laboratory, clinic, and hospitalization data were extracted from the database.
The data collected included the patients' age and weight at initiation of therapy, duration of therapy, viral genotype and load, and follow-up intervals for clinic visits and monitoring laboratory tests ( Clinic visit and hospital admission data were reviewed to determine if they were related to HCV infection (e.g., gastroenterology clinic or admission for hepatic dysfunction) or adverse effects from the therapy. Prescription data were assessed to evaluate the duration of therapy.
Patients were defined as having an appropriate duration of therapy if the length of therapy followed VA guidelines (Table 1) . Patients treated for a longer period of time than that defined as appropriate in the VA clinical practice guidelines were defined as having an excessive duration of therapy.
It was then determined whether patients had received the appropriate follow-up for their response to therapy as recommended by VA guidelines. All patients with documented sensitivity PCR assay detecting the presence or absence of HCV RNA at completion of therapy (24 or 48 weeks after initiation of therapy) were categorized as end-of-therapy responders (negative serum HCV RNA) or nonresponders (positive serum HCV RNA). Patients with detectable HCV RNA six months after completion of therapy were further categorized as sustained responders (negative serum HCV RNA) or relapsers (positive serum HCV RNA). This effectiveness measurement determines how well-controlled clinical trials compare with usual practice patterns.
Clinical follow-up (assessment of treatment adverse effects and guidance in adverse-effect management) and laboratory test follow-up were evaluated and defined as adequate if VA guidelines were met (Table 2) . If one visit to the HCV clinic was missed or one laboratory value was not recorded during the required interval, the follow-up was categorized as inadequate.
The percentage of patients who had reached a laboratory endpoint where dosage adjustments or discontinuation of therapy was needed was determined and the prescription information was compared to the hematologic data to determine if the dosages were adjusted appropriately in accordance with VA guidelines when evidence of hematologic toxicity was present (Table 3) .
The medical data of patients with HCV who were undergoing combination therapy were obtained from the written and computerized patient records. Study data were transferred to a Microsoft Access 2000 database (Microsoft Corp., Redmond, WA). The study was approved by the institutional review board and complied with the ethical standards established in the Declaration of Helsinki. 
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Results. Thirty-eight patients receiving the combination of interferon and ribavirin between 1998 and 2001 were identified. Patients' mean age was 49.5 ± 7.3 years, and 36 patients (95%) were men. Thirteen patients (34%) had genotype 1 HCV, 12 (32%) had genotype 2 or 3 HCV, and 13 (34%) had an unknown genotype. Those patients who had an unknown genotype were treated in 1998 and 1999, before genotyping became standard practice.
Thirty-five patients received an initial dosage of 3 million units of interferon three times weekly. For three patients, the initial dosage of interferon was only listed as "use as directed." Eleven patients received a starting dosage of ribavirin 1000 mg daily, and 27 patients received a starting dosage of ribavirin 1200 mg daily. The dosage was weight-adjusted for all patients.
The mean duration of therapy was 27.7 ± 15.4 weeks (range, 0.25-57 weeks). Nine patients (24%) received the treatment for less than 24 weeks, 13 (34%) received an appropriate duration of treatment, and 16 (42%) received treatment for an excessive duration. For those patients with an excessive duration of therapy, the mean excess treatment time was 10.3 weeks per patient (range, 3-29 weeks). The total excess duration of combination interferon-ribavirin therapy was 128-144 weeks. A twoweek interval was allowed for genotype 1 patients with a positive week-24 HCV RNA because the serology was sent to an outside facility and one to two weeks elapsed before the results became available (Table 1 ). In the nine patients who did not complete 24 weeks of therapy, the mean duration of treatment was 6.9 ± 7.2 weeks. Therapy was appropriately discontinued for the following reasons: adverse effects (n = 4), patients stopped getting care at our health care facility (n = 2), noncompliance (n = 1), therapy inappropriately started (negative HCV RNA) (n = 1), and an undocumented reason (n = 1).
Only 21 (72%) of the 29 patients who completed at least 24 weeks of therapy had their response assessed at the end of the treatment. Sustained response was assessed in 12 of 16 (75%) of the end-of-therapy responders (n = 8) and patients with an unknown end-of-therapy response (n = 8). End-of-therapy and sustained responses in patients who completed at least 24 weeks of therapy are shown in Table 4 . A low endof-therapy and sustained response was seen with genotype 1 infection (n = 1, 10%), while the response for genotype 2 and 3 patients declined between end of therapy and six months after the end of therapy (n = 5 [45%] and n = 4 [36%], respectively). Overall, the end-of-therapy response rate for the 38 patients who received interferon and ribavirin therapy was 21% (8/38) and the sustained response rate was 18% (7/38).
The clinical follow-up was adequate in 24 patients (63%). The ALT values had the highest rate of adequate follow-up (95%, n = 36) and TSH had the lowest rate (53%, n = 20). Among the 18 patients who did not receive the appropriate followup for the measurement of the TSH, 6 had no documented baseline TSH level, 9 did not get TSH follow-up while receiving treatment, and 2 did not have any TSH level documented in their records. CBC was adequately monitored in 25 patients (66%).
Hematologic adverse events were documented for three patients. Two patients had a hemoglobin decrease below 10 g/dL. In one, the ribavirin dosage was appropriately decreased to 600 mg daily, after which the hemoglobin increased to higher than 10 g/dL. When this patient was rechallenged with a ribavirin dose of 1000 mg daily, the hemoglobin dropped again below 10 g/dL; therefore the patient was permanently switched to 600 mg of ribavirin daily with no further complications and resolution of the low hemoglobin level. In the other patient, the dosage of ribavirin was not adjusted, and the hemoglobin level increased to over 10 g/dL by the next blood draw without complications.
One patient's platelet count fell below 50,000 cells/mm 3 . The dosage of interferon was not adjusted, and no clinical complications occurred. The subsequent CBC revealed a platelet count over 50,000 cells/mm 3 . None of the patients were hospitalized because of HCV infection or combination treatment.
Discussion. The study showed that the duration of therapy and laboratory monitoring for patients treated with the combination of ribavirin and interferon was suboptimal. The response to therapy was not systematically measured, even though response is the goal of the therapy. In this series, 2 (5%) of the patients developed anemia, but the CBC was not adequately monitored in 13 (34%) of the patients. Although the dosage of medication was not systematically adjusted because of adverse events in accordance with VA guidelines, hematologic toxicity resolved.
The excessive duration of therapy resulted in higher costs. The cost of The cost of excessive therapy will be higher with the use of pegylated interferon, indicating that a more systematic method of treating patients with HCV is needed. If a pharmacist saw 38 patients for half an hour at each clinic visit at weeks 1, 2, and 4 and then monthly, as is recommended in the guidelines, approximately 10% of a full-time pharmacist's salary would be devoted to the HCV clinic. This cost would remain below the cost associated with the extra weeks of therapy and would result in cost savings for the facility.
Although none of the hematologic adverse events or the supplemental clinic visits related to adverse events occurred during the excessive weeks of therapy, this excessive treatment exposes patients to unnecessary potential toxicity. This underscores the need for practitioners to adhere to the recommended guidelines on the appropriate discontinuation of therapy.
The response rate at the end of therapy of 21% and the sustained response rate of 18% observed in this study were lower than observed in previous trials. [6] [7] [8] It is possible that the effectiveness observed in this series is due to the small sample size or the fact that the response was not systematically assessed.
Conclusion. Clinical and laboratory monitoring of patients with HCV was suboptimal. An excessive duration of therapy led to increased costs and exposed patients to the risk of increased adverse events.
